ERR2278848
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.530
- ANGIOGENESIS+0.440
- ALLOGRAFT_REJECTION+0.330
- UV_RESPONSE_DN+0.320
- WNT_BETA_CATENIN_SIGNALING+0.280
- HEDGEHOG_SIGNALING+0.260
- TGF_BETA_SIGNALING+0.240
- KRAS_SIGNALING_UP+0.180
- IL2_STAT5_SIGNALING+0.150
- IL6_JAK_STAT3_SIGNALING+0.150
Top 10 suppressed
- MYC_TARGETS_V2-0.650
- MYC_TARGETS_V1-0.560
- OXIDATIVE_PHOSPHORYLATION-0.520
- MTORC1_SIGNALING-0.460
- FATTY_ACID_METABOLISM-0.380
- CHOLESTEROL_HOMEOSTASIS-0.370
- G2M_CHECKPOINT-0.370
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.370
- E2F_TARGETS-0.360
- P53_PATHWAY-0.360
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 6b32f047-89ca-40e7-950f-a03493ea90c7 | — | — | 0.885 |
| 2 | 102d912c-5882-4ae4-9eaf-cbd2f55f66af | — | — | 0.881 |
| 3 | c874c481-cff8-4e2d-99b1-3b5aeaaecb8e | — | — | 0.875 |
| 4 | SRR9879291 | — | cohortMD2 | 0.873 |
| 5 | TCGA-B6-A0IH-01A-11R-A115-07 | — | A | 0.869 |
| 6 | SRR26320068 | — | — | 0.866 |
| 7 | 3383d8e1-d61d-4346-a589-007ad2829e36 | — | — | 0.865 |
| 8 | SRR15069598 | — | — | 0.861 |
| 9 | SRR25043620 | — | — | 0.855 |
| 10 | SRR6013529 | — | cohortMD2 | 0.853 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 15 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.530 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.440 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.330 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.320 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.280 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.260 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.240 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.180 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.150 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.150 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.100 | Inavolisib | — uncovered |
| COMPLEMENT | 0.070 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.060 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.040 | Idelalisib | — uncovered |
| COAGULATION | 0.010 | Binimetinib | — uncovered |